A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs BL 8040 (Primary) ; Nelarabine (Primary)
- Indications Acute lymphoblastic leukaemia; Lymphoma
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 13 Dec 2016 Planned End Date changed from 1 Dec 2020 to 1 Apr 2021.
- 13 Dec 2016 Planned primary completion date changed from 1 Jan 2019 to 1 May 2019.